July 17, 2014 | Alcobra Pharmaceuticals filed a prospectus for a $100 million offering on NASDAQ. The company has developed alternative drugs for the treatment of ADHD based on its research. In May 2013, Alcobra’s IPO raised $25 million at a company value of $89 million. As of today, Alcobra is worth $260 million. The filing for the offering comes as Alcobra announces patient recruitment for Phase III clinical trials for its treatment for ADHD.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023

Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023

Israel Opens Its First Satellite Observatory
February 02, 2023

Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments